These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 10692272)

  • 1. Presence of sonographically detectable parathyroid glands can predict resistance to oral pulsed-dose calcitriol treatment of secondary hyperparathyroidism.
    Katoh N; Nakayama M; Shigematsu T; Yamamoto H; Sano K; Saito I; Nakano H; Kasai K; Kubo H; Sakai S; Kawaguchi Y; Hosoya T
    Am J Kidney Dis; 2000 Mar; 35(3):465-8. PubMed ID: 10692272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients.
    Fukagawa M; Kitaoka M; Yi H; Fukuda N; Matsumoto T; Ogata E; Kurokawa K
    Nephron; 1994; 68(2):221-8. PubMed ID: 7830860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism.
    Malberti F; Corradi B; Cosci P; Calliada F; Marcelli D; Imbasciati E
    Am J Kidney Dis; 1996 Nov; 28(5):704-12. PubMed ID: 9158208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcitriol pulse therapy and histology of parathyroid glands in hemodialysis patients.
    Lomonte C; Martino R; Selvaggiolo M; Bona RM; Cazzato F; Milano R; Chiarulli G; Basile C
    J Nephrol; 2003; 16(5):716-20. PubMed ID: 14733419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients.
    Shiizaki K; Negi S; Mizobuchi M; Hatamura I; Narukawa N; Sakaguchi T; Kitabata Y; Sumikado S; Akizawa T
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii42-6. PubMed ID: 12771299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Pulse oral' versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study.
    Bacchini G; Fabrizi F; Pontoriero G; Marcelli D; Di Filippo S; Locatelli F
    Nephron; 1997; 77(3):267-72. PubMed ID: 9375818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.
    Quarles LD; Yohay DA; Carroll BA; Spritzer CE; Minda SA; Bartholomay D; Lobaugh BA
    Kidney Int; 1994 Jun; 45(6):1710-21. PubMed ID: 7933819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of direct injection of calcitriol into the parathyroid glands in uraemic patients with moderate to severe secondary hyperparathyroidism.
    Nakanishi S; Yano S; Nomura R; Tsukamoto T; Shimizu Y; Shin J; Fukagawa M
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii47-9. PubMed ID: 12771300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percutaneous calcitriol injection therapy (PCIT) for secondary hyperparathyroidism: multicentre trial.
    Kitaoka M; Onoda N; Kitamura H; Koiwa F; Tanaka M; Fukagawa M
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii38-41. PubMed ID: 12771298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure.
    Ardissino G; Schmitt CP; Bianchi ML; Daccò V; Claris-Appiani A; Mehls O
    Kidney Int; 2000 Sep; 58(3):981-8. PubMed ID: 10972662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effect of intravenous calcitriol administration on secondary hyperparathyroidism. A double-blind study among 4 doses.
    Koshikawa S; Akizawa T; Kurokawa K; Marumo F; Sakai O; Arakawa M; Morii H; Seino Y; Ogata E; Ohashi Y; Akiba T; Tsukamoto Y; Suzuki M
    Nephron; 2002 Apr; 90(4):413-23. PubMed ID: 11961400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
    Sprague SM; Llach F; Amdahl M; Taccetta C; Batlle D
    Kidney Int; 2003 Apr; 63(4):1483-90. PubMed ID: 12631365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of calcitriol on parathyroid function and on bone remodelling in secondary hyperparathyroidism.
    Costa AF; dos Reis LM; Ribeiro MC; Moysés RM; Jorgetti V
    Nephrol Dial Transplant; 2003 Apr; 18(4):743-9. PubMed ID: 12637644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient.
    Rodriguez M; Caravaca F; Fernandez E; Borrego MJ; Lorenzo V; Cubero J; Martin-Malo A; Betriu A; Jimenez A; Torres A; Felsenfeld AJ
    Kidney Int; 1999 Jul; 56(1):306-17. PubMed ID: 10411707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size.
    Vulpio C; Maresca G; Distasio E; Cacaci S; Panocchia N; Luciani G; Bossola M
    Hemodial Int; 2011 Jan; 15(1):69-78. PubMed ID: 21223484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.
    Greenbaum LA; Grenda R; Qiu P; Restaino I; Wojtak A; Paredes A; Benador N; Melnick JZ; Williams LA; Salusky IB
    Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the effect of intravenous calcitriol on parathyroid gland activity using double-phase technetium Tc 99m-sestamibi scintigraphy.
    Torregrosa JV; Fuster D; Ybarra J; Ortín J; Moreno A; Valveny N
    Am J Kidney Dis; 2004 Sep; 44(3):476-80. PubMed ID: 15332220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients.
    Kitaoka M; Fukagawa M; Ogata E; Kurokawa K
    Kidney Int; 1994 Oct; 46(4):1110-7. PubMed ID: 7861705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effects of daily and intermittent-dose calcitriol on serum parathyroid hormone and ionized calcium concentrations in normal cats and cats with chronic renal failure.
    Hostutler RA; DiBartola SP; Chew DJ; Nagode LA; Schenck PA; Rajala-Schultz PJ; Drost WT
    J Vet Intern Med; 2006; 20(6):1307-13. PubMed ID: 17186842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.